

**FOR RELEASE, August 30th 2007**



**Contact :** Trinity Biotech plc  
Niamh Long  
(353)-1-2769800  
E-mail: [niamh.long@trinitybiotech.com](mailto:niamh.long@trinitybiotech.com)

## **Trinity Biotech Presenting at Roth Capital Partners Conference New York and Thomas Weisel Partners Healthcare Conference, Boston.**

DUBLIN, Ireland (August 30<sup>th</sup> 2007 )....Trinity Biotech plc (NASDAQ: TRIB, ISE:TRIB.I) a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced Brendan Farrell, President, will be speaking at the Roth Capital Partners New York Conference at 3.00 p.m. Eastern Time, on Wednesday the 5<sup>th</sup> of September. The event will be webcast and can be accessed on <http://www.roth.com/main/Page.aspx?PageID=7010>

Brendan Farrell, will also be speaking at the Thomas Weisel Partners Healthcare Conference in Boston at 11.30 a.m. Eastern Time, on Friday the 7<sup>th</sup> of September. This event will be webcast and can be accessed on : <http://www.veracast.com/webcasts/twp/healthcare07/00307400.cfm>

Trinity Biotech develops, acquires manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own salesforce and a network of international distributors and strategic partners.

Trinity Biotech trades its Ordinary Shares on the Irish Stock Exchange and ADR's on Nasdaq. Each ADR represents four Ordinary Shares. For further information please see the company's website: [www.trinitybiotech.com](http://www.trinitybiotech.com).

*Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.*